Niswender Laboratory

My current research is focused on the metabotropic glutamate receptor and cannabinoid receptor allosteric modulator drug discovery programs.  I work closely with others in the molecular pharmacology and chemistry groups to develop positive and negative modulators of mGlu and CB receptors for use as therapeutic agents for disease states such as depression, anxiety, and schizophrenia.  My mGlu work is centered on the group III mGlu receptors, including mGlu₇ and mGlu₈.  mGlu₇ is widely distributed in the CNS where mutations or deletions of the receptor result in symptoms of neurodevelopmental disorders such as Rett syndrome.   Preclinical studies have suggested that modulators of mGlu₈ may be beneficial in the treatment of various CNS disorders. We are currently developing new allosteric ligands that interact with and modulate group III mGlu receptors to better understand the involvement and therapeutic possibilities of these receptors.  I am also involved in the development of CB₂ PAMs as a new therapeutic approach for the treatment of schizophrenia and other CNS disorders. Our research provides insight into the complicated CB receptor pharmacology impacting new treatment strategies for brain disorders.